-transparent.png){kind=logo}
Primary tumours from 100 Norwegian node-negative breast carcinoma patients were examined for c-erbB-2, int-2, and c-myc proto-oncogene amplification. c-erbB-2, int-2, and c-myc amplification was found in 12.1% (12 of 99), 8.6% (8 of 93), and 1.1% (1 of 89) of the samples respectively. All the c-erbB-2 amplified tumours were of the ductal type, and all the int-2 amplified tumours were oestrogen receptor positive. No other significant or borderline significant associations between gene amplification and clinical or histopathological parameters were found. Relapse occurred more frequently in patients with c-erbB-2 gene amplification (relapse in 33.3% of the patients with c-erbB-2 amplification compared to 20.7% in the non-amplified group), but the difference was not statistically significant, int-2 amplification was not associated with increased risk of relapse, whereas the prognostic value of the c-myc amplification could not be evaluated.
L Ottestad, and
T I Andersen, and
J M Nesland, and
M Skrede, and
K M Tveit, and
K Nustad, and
A L Børresen
March 1993,
International journal of cancer,
L Ottestad, and
T I Andersen, and
J M Nesland, and
M Skrede, and
K M Tveit, and
K Nustad, and
A L Børresen
December 1997,
International journal of cancer,
L Ottestad, and
T I Andersen, and
J M Nesland, and
M Skrede, and
K M Tveit, and
K Nustad, and
A L Børresen
December 1989,
Cancer research,
L Ottestad, and
T I Andersen, and
J M Nesland, and
M Skrede, and
K M Tveit, and
K Nustad, and
A L Børresen
September 1996,
The Annals of thoracic surgery,
L Ottestad, and
T I Andersen, and
J M Nesland, and
M Skrede, and
K M Tveit, and
K Nustad, and
A L Børresen
January 1997,
Anticancer research,
L Ottestad, and
T I Andersen, and
J M Nesland, and
M Skrede, and
K M Tveit, and
K Nustad, and
A L Børresen
January 1991,
Cancer research,
L Ottestad, and
T I Andersen, and
J M Nesland, and
M Skrede, and
K M Tveit, and
K Nustad, and
A L Børresen
January 1996,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
L Ottestad, and
T I Andersen, and
J M Nesland, and
M Skrede, and
K M Tveit, and
K Nustad, and
A L Børresen
December 1992,
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
L Ottestad, and
T I Andersen, and
J M Nesland, and
M Skrede, and
K M Tveit, and
K Nustad, and
A L Børresen
October 1989,
British journal of cancer,
L Ottestad, and
T I Andersen, and
J M Nesland, and
M Skrede, and
K M Tveit, and
K Nustad, and
A L Børresen
September 1990,
Cancer research,
